Correction of Feline Lipoprotein Lipase Deficiency with Adeno-Associated Virus Serotype 1-Mediated Gene Transfer of the Lipoprotein Lipase S447X Beneficial Mutation
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Human lipoprotein lipase (hLPL) deficiency, for which there currently exists no adequate treatment, leads to excessive plasma triglycerides (TGs), recurrent abdominal pain, and life-threatening pancreatitis. We have shown that a single intramuscular administration of adeno-associated virus (AAV) serotype 1 vector, encoding the human LPL(S447X) variant, results in complete, long-term normalization of dyslipidemia in LPL(/) mice. As a prelude to gene therapy for human LPL deficiency, we tested the efficacy of AAV1-LPL(S447X) in LPL(/) cats, which demonstrate hypertriglyceridemia (plasma TGs, >10,000 mg/dl) and clinical symptoms similar to LPL deficiency in humans, including pancreatitis. Male LPL(/) cats were injected intramuscularly with saline or AAV1-LPL(S447X) (1 x 10(11)-1.7 x 10(12) genome copies [GC]/kg), combined with oral doses of cyclophosphamide (0-200 mg/m(2) per week) to inhibit an immune response against hLPL. Within 3-7 days after administration of >or=5 x 10(11) GC of AAV1-LPL(S447X) per kilogram, the visible plasma lipemia was completely resolved and plasma TG levels were reduced by >99% to normal levels (10-20 mg/dl); intermediate efficacy (95% reduction) was achieved with 1 x 10(11) GC/kg. Injection in two sites, greatly limiting the amount of transduced muscle, was sufficient to completely correct the dyslipidemia. By varying the dose per site, linear LPL expression was demonstrated over a wide range of local doses (4 x 10(10)-1 x 10(12) GC/site). However, efficacy was transient, because of an anti-hLPL immune response blunting LPL expression. The level and duration of efficacy were significantly improved with cyclophosphamide immunosuppression. We conclude that AAV1-mediated delivery of LPL(S447X) in muscle is an effective means to correct the hypertriglyceridemia associated with feline LPL deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 1×
“Most widely used is AAV serotype 2 (AAV2), but several groups have demonstrated that AAV1, AAV7, and AAV8 transduce muscle cells efficiently (Xiao et al ., 1999; Chao et al ., 2000, 2001; Arruda et al ., 2004; Louboutin et al ., 2005), which is of interest as muscle represents one of the natural…”
Jooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 1×
“Studies indicate that after rAAV-mediated protein expression in muscle there is cross-presentation of antigens in the draining lymph nodes close to the injection site (Jooss et al ., 1998; Wang et al ., 2005a,b).”
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366
Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element
Donello, J. E., Loeb, J. E., & Hope, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5085-5092.1998 · Cited by 350 · cited 1×
“The bovine growth hormone polyadenylation sequence [bGH poly(A)] and woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) were added to enhance transcription (Donello et al ., 1998).”
Grimm, D., Kay, M. A., & Kleinschmidt, J. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00095-9 · Cited by 344 · cited 2×
“Recombinant AAV serotype 1 was produced by calcium phosphate-mediated cotransfection in 293 cells, using a two plasmid-based method (Grimm et al ., 2003).”
Wittrup, H. H., Tybjærg-Hansen, A., & Nordestgaard, B. G. (1999) · Circulation · doi:10.1161/01.cir.99.22.2901 · Cited by 344
Herzog, R. W., Mount, J. D., Arruda, V. R., High, K. A., & Lothrop, C. D. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0442 · Cited by 176
Fields, P. A., Arruda, V. R., Armstrong, E., Chu, K., Mingozzi, F., Hagstrom, J. N., Herzog, R. W., & High, K. A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0441 · Cited by 127
Research works printed but not linked: 31
- 10.1182/blood-2003-05-1446 · DOI · Paper page
- BIJVOET S., 1996, J. Lipid Res., 37, 640, 10.1016/S0022-2275(20)37605-7 · DOI · Paper page
- 10.1038/sj.gt.3301024 · DOI
- 10.1006/mthe.2001.0449 · DOI · Paper page
- 10.1161/01.ATV.17.11.2532 · DOI
- 10.1006/mthe.2000.0032 · DOI · Paper page
- 10.1034/j.1399-0004.1999.550609.x · DOI · Paper page
- 10.1073/pnas.182412299 · DOI · Paper page
- 10.1172/JCI118541 · DOI · Paper page
- 10.1046/j.1365-2362.1999.00435.x · DOI · Paper page
- GOLDBERG I.J., 1996, J. Lipid Res., 37, 693, 10.1016/S0022-2275(20)37569-6 · DOI · Paper page
- 10.1161/01.CIR.95.12.2628 · DOI · Paper page
- 10.1073/pnas.94.11.5804 · DOI · Paper page
- 10.1038/73464 · DOI · Paper page
- 10.4049/jimmunol.166.10.6099 · DOI · Paper page
- 10.1089/10430340050016120 · DOI · Paper page
- 10.1002/jgm.686 · DOI · Paper page
- 10.1182/blood.V97.5.1258 · DOI · Paper page
- NIERMAN M.C., 2005, Neth. J. Med., 63, 14
- ORANJE P.P., 2004, Mol. Ther., 9, S162
- 10.1089/hum.2005.16.1276 · DOI · Paper page
- 10.1089/hum.2004.15.906 · DOI · Paper page
- 10.1128/JVI.75.1.269-277.2001 · DOI · Paper page
- 10.1002/jgm.175 · DOI · Paper page
- 10.1073/pnas.95.24.14384 · DOI · Paper page
- 10.1074/jbc.M104430200 · DOI · Paper page
- 10.1089/104303402760128577 · DOI · Paper page
- 10.1073/pnas.96.7.3906 · DOI · Paper page
- 10.1038/sj.gt.3302539 · DOI
- 10.1182/blood-2004-03-0848 · DOI · Paper page
- WATSON T.D., 1995, Am. J. Vet. Res., 56, 289, 10.2460/ajvr.1995.56.03.289 · DOI
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Self-citationMingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Self-citationStroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.175620 · Cited by 209
Self-citation
Metadata
- Authors
- Ross, C. J. D., Twisk, J., Bakker, A. C., Miao, F., Verbart, D., Rip, J., Godbey, T., Dijkhuizen, P., Hermens, W. T. J. M. C., Kastelein, J. J. P., Kuivenhoven, J. A., Meulenberg, J. M., & Hayden, M. R.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2006-05
- Volume
- 17
- Issue
- 5
- Pages
- 487-499
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2025763389
- Cited by
- 82
- References
- 9
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.